Scinai Immunotherapeutics LT
13F holders, Q1 2026 (March 31)4holders −3
0new positions
3sold out
$0.55avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Scinai Immunotherapeutics LT in their 13F filings, down 3 from Q4 2025. 0 opened new positions and 3 sold out. The largest holders were XTX Topco Ltd ($13K), Rhumbline Advisers ($1K) and UBS Group AG ($524).
- Company
- Scinai Immunotherapeutics LT
- CUSIP
- 09073Q303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $36K |
All 13F filers, Q4 2025 → Q1 2026: 55,053 shares sold, net −55,053 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| XTX Topco Ltd | 0.00% | Reduce -11.9% | 24,041 | $13K |
| Rhumbline Advisers | 0.00% | No change | 1,878 | $1K |
| UBS Group AG | 0.00% | Reduce -47.4% | 919 | $524 |
| Morgan Stanley | 0.00% | No change | 58 | $33 |
"% of holder's portfolio" is SCINAI IMMUNOTHERAPEUTICS LT's weight in each manager's 13F, not the share of Scinai Immunotherapeutics LT the manager owns.